![Table 2 from ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. | Semantic Scholar Table 2 from ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7b06aa27f024f841baccaf318285c56a44ed01c6/3-Table3-1.png)
Table 2 from ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. | Semantic Scholar
![Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519) - ScienceDirect Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519) - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419382948-gr1.jpg)
Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519) - ScienceDirect
![Pediatric Hodgkin Lymphoma Treated at Cancer Institute, Chennai, India: Long-Term Outcome | JCO Global Oncology Pediatric Hodgkin Lymphoma Treated at Cancer Institute, Chennai, India: Long-Term Outcome | JCO Global Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jgo/2017/jgo.2017.3.issue-5/jgo.2016.005314/20171005/images/large/jgo.2016.005314t3.jpeg)
Pediatric Hodgkin Lymphoma Treated at Cancer Institute, Chennai, India: Long-Term Outcome | JCO Global Oncology
![ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial - ScienceDirect ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419348252-gr1.jpg)
ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial - ScienceDirect
![Efficacy and Safety of Brentuximab Vedotin with ABVD or AVD in Newly Diagnosed Advanced HL | Research To Practice Efficacy and Safety of Brentuximab Vedotin with ABVD or AVD in Newly Diagnosed Advanced HL | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/2011/5MJCASH2012/2/5/Slide3.jpg)
Efficacy and Safety of Brentuximab Vedotin with ABVD or AVD in Newly Diagnosed Advanced HL | Research To Practice
![Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease | NEJM Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2003/nejm_2003.348.issue-24/nejmoa022473/production/images/img_medium/nejmoa022473_t4.jpeg)
Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease | NEJM
![Classical Hodgkin's lymphoma: past, present and future perspectives | British Journal of Hospital Medicine Classical Hodgkin's lymphoma: past, present and future perspectives | British Journal of Hospital Medicine](https://www.magonlinelibrary.com/cms/10.12968/hmed.2013.74.11.612/asset/images/medium/hmed.2013.74.11.612_t04.jpg)
Classical Hodgkin's lymphoma: past, present and future perspectives | British Journal of Hospital Medicine
![EARLY HIGH-DOSE SALVAGE AFTER “ABVD X 2 FAILURE” IN HODGKIN'S.... EHA Library. Olivieri J. Jun 12 2020; 298083 EARLY HIGH-DOSE SALVAGE AFTER “ABVD X 2 FAILURE” IN HODGKIN'S.... EHA Library. Olivieri J. Jun 12 2020; 298083](https://library.ehaweb.org/image/abstracts/eha_2020/EHA-4087/ImagePictures_7736686.png)
EARLY HIGH-DOSE SALVAGE AFTER “ABVD X 2 FAILURE” IN HODGKIN'S.... EHA Library. Olivieri J. Jun 12 2020; 298083
![Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease | NEJM Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2003/nejm_2003.348.issue-24/nejmoa022473/production/images/img_medium/nejmoa022473_t3.jpeg)
Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease | NEJM
![Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00277-021-04460-9/MediaObjects/277_2021_4460_Fig1_HTML.png)
Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up
![Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin's Lymphoma (HL) in the ABVD Therapeutic Era - Biology of Blood and Marrow Transplantation Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin's Lymphoma (HL) in the ABVD Therapeutic Era - Biology of Blood and Marrow Transplantation](https://www.astctjournal.org/cms/attachment/bd2076b2-16bd-45c1-913a-2da2da1947f2/gr1.jpg)
Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin's Lymphoma (HL) in the ABVD Therapeutic Era - Biology of Blood and Marrow Transplantation
![Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease | NEJM Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2003/nejm_2003.348.issue-24/nejmoa022473/production/images/img_medium/nejmoa022473_t1.jpeg)
Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease | NEJM
![Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies | Blood Cancer Journal Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies | Blood Cancer Journal](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41408-021-00518-z/MediaObjects/41408_2021_518_Fig1_HTML.png)
Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies | Blood Cancer Journal
![PDF) A phase II study of dose-dense and dose-intense ABVD (ABVD DD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma | Daniela Donnarumma - Academia.edu PDF) A phase II study of dose-dense and dose-intense ABVD (ABVD DD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma | Daniela Donnarumma - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/47245417/mini_magick20190207-6711-1v2p72m.png?1549566480)